Tenecteplase Boehringer Ingelheim Pharma GmbH Co. KG (tenecteplase)
- Region
- 🇪🇺 EU
- Active substance
- tenecteplase
- Company
- Boehringer Ingelheim International GmbH
- Status
- Withdrawn
- Therapeutic area
- Myocardial Infarction
- EU approval
- Fri 23 Feb 2001
- Application
- EMEA/H/C/000307
- ATC
- B01AD
- Official record
- www.ema.europa.eu
Indication
Tenecteplase Boehringer Ingelheim Pharma GmbH Co. KG is indicated for the thrombolytic treatment of suspected myocardial infarction with persistent ST elevation or recent left Bundle Branch Block within 6 hours after the onset of acute myocardial infarction (AMI) symptoms.
Regulatory milestones
No milestones recorded in the last year.
Same substance in other markets
- 🇪🇺 Metalyse Authorised · Boehringer Ingelheim International GmbH
Follow Tenecteplase Boehringer Ingelheim Pharma GmbH Co. KG
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.